NCT01275287: Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab |
|
|
| Withdrawn | 2 | 0 | US | Standard of care treatment, cytoxan, eculizumab, Soliris | University of North Carolina, Chapel Hill, Alexion Pharmaceuticals, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 12/12 | 12/12 | | |
NCT01756508: Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury |
|
|
| Completed | 2 | 57 | RoW | eculizumab, Soliris | Russian Academy of Medical Sciences | End-Stage Renal Disease, Kidney Failure, Graft Reperfusion Injury | 04/17 | 12/17 | | |
